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Abstract 
Proteins are organic macromolecules essential in life but exploited, mainly in recombinant 
versions, as drugs or vaccine components, among other uses in industry or biomedicine. In 
oncology, individual proteins or supramolecular complexes have been tailored as small 
molecular weight drug carriers for passive or active tumor cell-targeted delivery, through the de 
novo design of appropriate drug stabilizing vehicles, or by generating constructs with different 
extents of mimesis of natural cell-targeted entities, such as viruses. In most of these approaches, 
a convenient nanoscale size is achieved through the oligomeric organization of the protein 
component in the drug conjugate. Among the different taken strategies, highly cytotoxic 
proteins such as microbial or plant toxins have been conveniently engineered to self-assemble 
as self-delivered virus-like, nanometric structures, chemically homogeneous, that target 
metastatic cancer stem cells for destruction of metastasis in absence of any partner vehicle. 
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Introduction  
Proteins are essential macromolecules in life that combine structural and biological 
functionalities including catalysis, signaling and precise interaction with targets. By recombinant 
DNA technologies or by chemical synthesis, full-length proteins or short peptides are produced 
and engineered to mimic natural versions or to generate novel activities. In this context, proteins 
are used in industrial catalysis, in research and development and as vaccines or drugs for clinical 
applications [1]. Most drug proteins are substitutes of endogenous enzymes or hormones absent 
in the patient’s body. However, proteins are also explored as partners of conventional small 
molecular weight drugs and nucleic acids, to confer stability, nanoscale size and cell penetrability 
or specific targeting, of which conventional medicines are generically devoid. Nanoscale size of 
the vehicle-drug complex is desirable not only to improve the EPR effect and cell penetrability 
but also to minimize renal filtration, that shows a cut-off of 6-8 nm [2]. Cell-targeted drug 
delivery is specifically demanded in the case of cytotoxic agents (mainly used in oncology), that 
lacking selectivity cause severe side effects [3]. This leads to minimized doses to keep toxicity 
within acceptable levels, with the consequent reduction of the actual effectiveness. To reach 
nanoscale and targeting, drug designers exploit natural or bioinspired agents such as natural 
viruses or virus-like particles, de novo designed protein oligomers, engineered polypeptides and 
short peptides. Under these premises, the most explored protein-based drug delivery 
approaches in oncology are summarized in the following sections and schematized in Figure 1.  
 
Protein and polyamino acid-based nanoparticles 
Albumin-based nanoparticles use Nab coacervation technology to increase solubility, half-life, 
stability and safety of the payload drug, although without conferring any cell targeting in the 
delivery process [4]. Nab-paclitaxel (Abraxane®) is an albumin-stabilized nanoparticle of 
paclitaxel approved by the FDA (2005) and EMA (2013) for advanced breast cancer therapy [4]. 
Its combination with carboplatin or gemcitabine is used for non-small cell lung (NSCLC) [5] and 
pancreatic [6] cancer therapy, respectively. Paclitaxel enters tumor cells and stabilizes 
microtubules, preventing their depolymerization and yielding antineoplastic activity through 
inhibition of cell motility, mitosis and replication. Despite the induction of neutropenia, fatigue 
and neuropathy, AbraxaneTM increases tolerance compared to free paclitaxel, allowing its 
administration at higher dosage with greater efficacy [7]. Other albumin-stabilized nanoparticles 
are Nab-docetaxel and Nab-rapamycin. Nab-docetaxel incorporates the taxane microtubule 
inhibitor Docetaxel and is in preclinical testing [8]. Nab-rapamycin binds water-insoluble 
rapamycin to the albumin nanoparticle. Its antineoplastic activity is mediated by rapamycin-
induced immunosuppressant and antiangiogenic effects after tumor and endothelial cell uptake 
[9]. Nab-Rapamycin is being tested in a phase II clinical trial in advanced malignant perivascular 
epithelioid cell tumors, and in Phase I/II for non-muscle invasive bladder cancer therapy. 
Conjugation to polymeric nanoparticles is another strategy to increase solubility while reaching 
a nanometric size, minimizing renal clearance and expanding the drug half-life in blood. The 
polymer Paclitaxel-polyglutamate links the drug to this biodegradable, water-soluble polymer 
that allows the delivery of higher doses than paclitaxel alone [10]. Phase I/II clinical trials are 
ongoing for the treatment of NSCLC, glioblastoma, and ovarian and head and neck cancers. 
Pegaspargase (Oncaspar®) conjugates polyethylene glycol to the enzyme L-asparaginase to limit 
clearance by the mononuclear phagocytic system. L-Asparagine is critical for protein synthesis 
in leukemic cells, unlike normal cells [11]. Asparaginase hydrolyzes asparagine, thereby 
depleting cells of asparagine and blocking protein synthesis to induce tumor cell death. 
Oncospar® was approved by the FDA (2006) and EMA (2016) as a component of a multi-agent 
chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia.   
 
Virus-based strategies 
Nanoscale cancer drugs include genetically modified viruses, whose activity is based on three 
different therapeutic approaches, namely gene therapy, vaccination and oncolysis. Viral gene 
therapy utilizes replication incompetent viruses to transfer genetic material to cancer cells, 
either to restore tumor suppressor gene expression, to reduce the expression of activated 
oncogenes or to express suicide genes. Current strategies have been demonstrated to be safe 
in early clinical trials but mostly show low therapeutic effect due to due to the small number of 
cancer cells that are infected and to immune system blockade [12]. Only Gendicine® (rAd-p53) 
was approved in 2003 in China for systemic cancer (head and neck) therapy. Its combined 
administration with chemo and radiotherapy yields higher response rates than standard 
treatments [13]. 
Viral-based cancer vaccines are immunotherapeutics that use non-replicating viruses encoding 
tumor antigens, co-stimulatory molecules or cytokines [14]. Ongoing Phase III clinical trials are 
evaluating adenovirus Instiladrin® (rAD-IFN/Syn3) and vaccinia virus PROSTVAC®, for the 
treatment of bladder [15] or prostate [16] cancer, respectively. The clinical progress of virus-
based vaccines has been hampered, however, by tumor immune evasion and heterogeneous 
immune responses among patients [17]. 
Oncolytic viruses (OVs) appear to solve virus-based gene therapy and cancer vaccines limitations 
since they are competent to replicate in tumor cells, but inactive in normal cells. Subsequently, 
they trigger cancer cell lysis and progeny virus spread that infects nearby cells. OVs show also 
an immunostimulating effect against cancer cells, by recruiting antigen-presenting cells or T cells 
to the tumor, reducing microenvironment-mediated immunosuppression and enhancing tumor 
antigen presentation in cancer cells [18]. The efficacy and reduced toxicity of specific OVs in 
preclinical studies, prompted their testing in clinical trials.  
In 2015, the FDA approved the first OV, a modified HSV named Imlygic® (T-VEC), for the 
treatment of melanoma patients [19]. Ongoing Phase III clinical trials are evaluating vaccinia 
virus Pexa-Vec® for liver cancer therapy, adenovirus CG0070 for bladder cancer, and reovirus 
Reolysin® for HNC and retrovirus Toca 511® for glioblastoma (www.clinicaltrials.gov). Additional 
approaches using different virus types are showing promising results in early clinical phases 
(www.clinicaltrials.gov; [20]. Despite their potential advantages, the therapeutic efficacy of OVs 
as single agents is hampered by their reduced systemic delivery, and limited spread or 
maintenance in the tumor microenvironment [18, 21]. Multimodality approaches combining 
OVs or virus-based vaccines with chemotherapy, radiotherapy or immune checkpoint inhibitors 
hold the greatest promise for clinical success. 
 
Antibody-Drug Conjugates 
To gain selectivity for tumor cells, Antibody Drug Conjugates (ADCs) are designed to specifically 
deliver highly cytotoxic drugs. ADCs consist of a monoclonal antibody covalently linked to an 
antitumor agent. Their effectiveness depends mostly on the differential expression of the target 
antigen in tumor cells compared to normal cells, the stability of the linker and the payload drug 
selection [22]. Most ADCs in clinical development use derivatives of potent antimitotic 
microtubule-disrupting agents (e.g., auristatins or maytansinoids) or highly cytotoxic DNA 
damaging agents (e.g., calicheamicins or duocarmycins). Despite the fact that more than 80 
ADCs have entered clinical trials, over the last 15 years, only four reached the market. 
Gemtuzumab ozogamicin (Mylotarg®) was in 2000 the first FDA-approved ADC. This is a 
calicheamicin-antibody conjugate that targets the myeloid antigen CD33. It was used as single 
agent to treat old acute myeloid leukemia patients in first relapse but was withdrawn from US 
and Europe in 2010 due to toxicity concerns. However, in 2017, the FDA reapproved it with a 
lower recommended dosage [23]. Brentuximab vedotin (Adcetris) was approved in 2011 for the 
treatment of Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma, which is a 
conjugate of monomethyl auristatin E and an anti-CD30 antibody [24].  
The first and only ADC approved for solid neoplasias is Ado-Trastuzumab Emtansine (Kadcyla), 
an anti-HER2 antibody conjugated to the maytansinoid DM1 through a non-cleavable linker, for 
the treatment of HER2-positive metastatic breast cancer [25]. Recently, Inotuzumab ozogamicin 
(Besponsa®), a calicheamicin targeted to CD22 B-cell antigen, has been approved for the 
treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia 
[26]. Although several ADCs have demonstrated effectiveness in clinical trials, resistance to 
these drugs usually happens as with other antitumor agents. The mechanisms of acquired 
resistance are diverse and include changes in the expression levels of the antigen recognized by 
the mAb, alteration in the ADC internalization and trafficking pathways, impaired lysosomal 
function and drug elimination by efflux pumps [27]. Consequently, different strategies are also 
under evaluation to overcome resistance to ADCs, such as the development of new mAb formats 
(e.g. bispecific or biparatopic) that target HER2 and/or prolactin [28, 29]. Another promising 
approach is the combination of ADCs with immunotherapies, such as PD-L1 and PD-1 inhibitors, 
expected to show synergistic antitumor activity [30].  
 
Virus-like particles 
To combine the advantages of viral drug carriers and ADCs, namely protein cages and cell 
targeting, virus like particles (VLPs), mostly explored as vaccine components, have been adapted 
as drug delivery systems [31]. Since they are produced by recombinant DNA technologies, 
selectivity can be incorporated by inserting a targeting protein domain into an exposed surface 
loop of the viral capsid protein [32, 33]. Cargo drug molecules can be encapsulated within VLPs 
through different approaches, including external display by direct genetic fusion or 
bioconjugation, or internal drug encapsulation by direct genetic fusion, internal bioconjugation, 
nucleic acid driven non-covalent direct encapsulation, electrostatic or protein domain driven 
interactions or physical entrapment during in-vitro re-assembling [34].  
Different molecules have been encapsulated within VLPs for targeted delivery in cancer. In this 
sense, MS2 phage coat protein VLPs displaing either TAT or transferin were used to deliver 
microRNA or siRNA respectively to human carcinoma cells [35, 36]. Also, ricin toxin (A-chain) has 
been encapsulated in targeted MS2 phage VLPs and delivered to human hepatocelular 
carcinoma cells inducing potent caspase 3 apoptosis activation [37]. Phage derived VLPs (Qβ, 
P22 and MS2 among others) have been also adapted to deliver active enzymes. For example, 
cytochrome P450 was successfully encapsulated in P22 VLPs and selectively delivered to human 
cervix and breast carcinoma cells via folate receptor for pro-drug activation in target cells [38]. 
JC polyomavirus VLPs were explored to deliver a suicide gene to human lung adenocarcinoma 
[39]. Johnson grass chlorotic stripe mosaic VLPs produced in tobacco cells have been recently 
loaded with antitumor doxorubicin [40], and targeted Rous sarcoma VLPs produced in Silkworm 
specifically delivered encapsulated doxorubicin in colon carcinoma cell lines [41]. In a more 
innovative approach, Rous sarcoma VLPs were double functionalized with a targeting and 
therapeutic moiety to specifically deliver Interleukin-2 (IL-2) to colon carcinoma cell lines and 
induce macrophage attraction [42].  
Co-specific delivery of diverse cargos has also appeared as very promising strategy against 
cancer. For instance, potent synergic effects were achieved over human hepatocellular 
carcinoma by the co-administration of doxorubicin conjugated and small anionic nucleotide 
conjugated adenovirus dodecahedron VLPs [43]. Targeted delivery of a cocktail of small 
molecular weight drugs by MS2 phage VLPs also selectively killed human hepatocellular 
carcinoma cells in a very efficient way [37]. Finally, theranostic approaches have been also 
explored, where naturalized hepatitis B core protein VLPs have been adapted for targeted 
delivery of indocyanine green molecule into human glioblastoma cells for imaging and 
photothermal therapy [44]. 
Even though the use of VLPs as protein nanocontainers for targeted drug delivery is widely 
explored, their intrinsic immunogenecity has often limited their use in nanomedicine [45]. In this 
context, many efforts have been made to reduce VLP immunogenicity for drug delivery 
approaches. As an example, an E. coli based cell-free protein synthesis platform produced 
modified hepatitis B core protein VLPs with no immunogenicity in mice [46]. 
 
Peptides and proteins 
In a simpler approach, peptides and proteins as drug targeting moieties show advantages over 
antibodies or VLPs, since they have high tumor penetrability linked to their smaller size, and get 
to a lesser extent trapped by the reticuloendothelial system (RES). Peptides are less 
immunogenic than full-length proteins or viral capsids but more prone to be degraded. This issue 
can be overcome by designing peptides with D-isoform amino acids, cyclation, the use of the 
retro-inverso version or by different modifications on their chemistry. Over the last decade, the 
application of combinatorial phage display, one-bead one-compound libraries and molecular 
modeling have rendered new tumor homing peptides (THPs). Those collected until 2012 are 
available at TumorHoPe database (http://crdd.osdd.net/raghava/tumorhope/). Furthermore, 
the term aptide has been coined recently to refer to artificial aptamer-like peptide ligands that 
can mimic the DNA recognition site of basic leucine zipper (bZIP) proteins [47]. Moreover, the in 
silico design of tumor homing peptides through a computational approach is now feasible [48].  
From the extensive peptide catalogue obtained, a bunch of proteins and peptides have been 
assessed in preclinical studies, as nicely summarized [49]. A number of peptides have been 
incorporated into cargo-bearing therapeutic nanoparticles of varying types, to target not only 
tumor cells through specific receptors overexpressed on the cell surface, but also components 
of the tumor microenvironment like blood vessels (for instance RGD, iRGD and ATN-161 that 
bind integrins, Qa-based peptide analog of sLex and Esbp that target E- and P- selectin, NGR 
towards CD13, F3 to nucleolin, CREKA to fibrin-fibronectin complexes, F56 to VEGFR-1, A7R to 
NRP-1 receptor, SP5-52 with unknown receptor, etc) [50] and lymphatic vessels (Lyp-1 and Syp-
1 directed to p32 protein). This has been very well documented [51], and some examples will 
discussed in other reviews within this special section. Apart from THPs, a few natural proteins 
intrinsically target nanomedicines to tumoral tissues. Transferrin binds and internalizes through 
the transferrin receptor overexpressed in different tumors, wheat germ agglutinin (WGA) binds 
sialic acid and other carbohydrates, the synthetic ankyrin repeat proteins bind the epithelial cell 
adhesion molecule (EpCAM) and chlorotoxin recognizes αvβ3, annexin-A2 and MMP2 [52, 53]. 
Besides the outstanding effort to confer active targeting to drugs, there are only a few examples 
of nanomedicines using proteins/peptides to target tumor tissue in clinical trials. For instance,   
liposomal/polymeric nanoparticles bound to transferrin (Tf) selectively deliver oxaliplatin or 
siRNA in cancer cells because of their high Tf receptor overexpression [51]. Apart from that, it 
has to be considered that tumor homing capabilities through a specific receptor do not 
necessarily include cell penetration, an essential feature when dealing with intracellular 
antitumoral effects. In this context it has been observed that THPs with a R/KXXK/R consensus 
sequence (termed C-end rule, CendR) also show intracellular penetration, fact that boost the 
creation of iRGD, iNGR, tLyp-1 and other THPs containing CendR sequences [54]. In this context, 
the concept of tumor homing cell penetrating peptides (THCPPs) with both tumor homing and 
cell internalization abilities, has been already coined [55]. 
 
Viral mimetics 
Combining the functionality of short peptides, the versatility in the genetic engineering of full-
length proteins and the nanoscale oligomeric organization of viral capsids would be highly 
desirable when approaching the design of new and more effective antitumoral drugs or drug 
vehicles. In this context, de novo designed oligomeric protein constructs,  measuring 12-40 nm 
and that mimic features of viral capsids without the involvement of infectious material, have 
been recently generated by using a simple protein engineering platform [56, 57]. These 
constructs, avoiding potential viral-associated immune responses, can be empowered by 
genetic fusion with peptidic ligands of relevant tumoral markers such CD44 or CXCR4 [58-60]. 
Under an ADC-like concept, the multivalent presentation of these ligands dramatically favors 
cell penetration and enhances effectiveness of any linked drug [61]. A CXCR4-targeted 
oligomeric vehicle, conjugated with a polymeric form of 5-fluorouracyl, has been recently shown 
as extremely potent against metastatic colorectal cancer in mouse models of the human disease 
[62]. Taking the same principle, several microbial and plant toxins, among those explored as 
cytotoxic agents in oncology [63], have been engineered to self-assemble as CXCR4-targeted 
oligomers, that upon systemic injection, result in self-targeted self-delivered drugs. No external 
nanoscale vehicle is there required, following the emerging concept of vehicle-free nanoscale 
drugs [2]. Nanostructured diphtheria toxin and ricin derivatives have been proven to be highly 
potent in colorectal cancer and acute myeloid leukemia in vivo models, respectively [64, 65], 
while the incorporation of human pro-apoptotic factors [66], instead of foreign toxins, would 
minimize the risk of undesired immune responses to this new category of nanostructured 
protein-based antitumoral drugs. 
 
Conclusions 
Protein-based technologies for nanoscale drug design offer functional and structural versatility 
that allows high selectivity in the delivery process through specific interaction with cell surface 
markers. The combination of functional peptides with cage-like supramolecular assemblies 
allow the generation of smart vehicles and selective drug carriers in form of viral mimetics, but 
beyond the most conventional use of viruses or VLPs. 
 
Acknowledgments. The authors acknowledge the Agencia Estatal de Investigación (AEI) and 
Fondo Europeo de Desarrollo Regional (FEDER) (grant BIO2016-76063-R, AEI/FEDER, UE), 
AGAUR (2017SGR-229) and CIBER-BBN (project NANOPROTHER and VENOM4CANCER) granted 
to AV, Marató de TV3 foundation (TV32013-3930) and ISCIII (PI15/00272 co-founding FEDER) to 
EV and ISCIII (PI15/00378 and PIE15/00028, co-founding FEDER), Marató de TV3 foundation 
(TV32013-2030) and AGAUR 2014-PROD0005 to RM, for funding research on protein based drug 
delivery. This has also involved the ICTS “NANBIOSIS”, more specifically the Protein Production 
Platform of CIBER-BBN/ IBB (http://www.nanbiosis.es/unit/u1-protein-production-platform-
ppp/). AV received an ICREA ACADEMIA award. 
 
References 
 
[1] Sanchez-Garcia L, Martin L, Mangues R, Ferrer-Miralles N, Vazquez E, Villaverde A. 
Recombinant pharmaceuticals from microbial cells: a 2015 update. Microbial cell factories 
2016;15:33. 
[2] Shen J, Wolfram J, Ferrari M, Shen H. Taking the vehicle out of drug delivery. Materials today 
2017;20:95-7. 
[3] Mangues RV, E; Villaverde, A. Targeting in Cancer Therapies. Medical Sciences 2016;4:6. 
[4] Yu X, Jin C. Application of albumin-based nanoparticles in the management of cancer. Journal 
of materials science Materials in medicine 2016;27:4. 
[5] Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. 
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus 
carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final 
results of a phase III trial. J Clin Oncol 2012;30:2055-62. 
[6] Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in 
pancreatic cancer with nab-paclitaxel plus gemcitabine. The New England journal of medicine 
2013;369:1691-703. 
[7] Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: a review of 
nanotherapeutics currently undergoing clinical trials. Wiley interdisciplinary reviews 
Nanomedicine and nanobiotechnology 2017;9. 
[8] Joerger M. Treatment regimens of classical and newer taxanes. Cancer chemotherapy and 
pharmacology 2016;77:221-33. 
[9] Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, et al. 
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of 
a phase I trial. Clinical cancer research : an official journal of the American Association for Cancer 
Research 2013;19:5474-84. 
[10] Wang Y, Liu J, Zhang J, Wang L, Chan J, Wang H, et al. A cell-based pharmacokinetics assay 
for evaluating tubulin-binding drugs. International journal of medical sciences 2014;11:479-87. 
[11] Schutz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M, NanoImpactNet C. 
Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine 2013;8:449-67. 
[12] McCormick F. Cancer gene therapy: fringe or cutting edge? Nature reviews Cancer 
2001;1:130-41. 
[13] Zhang WW, Li L, Li D, Liu J, Li X, Li W, et al. The First Approved Gene Therapy Product for 
Cancer Ad-p53 (Gendicine): 12 Years in the Clinic. Human gene therapy 2018;29:160-79. 
[14] Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current 
vaccines. Nature medicine 2004;10:909-15. 
[15] Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, et al. Intravesical rAd-
IFNalpha/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed 
Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol 2017;35:3410-
6. 
[16] Singh H, Madan RA, Dahut WL, Strauss J, Rauckhorst M, McMahon S, et al. Combining active 
immunotherapy and immune checkpoint inhibitors in prostate cancer. J Clin Oncol 
2015;33:e14008-e. 
[17] Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer journal 
2011;17:359-71. 
[18] Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic viruses as 
engineering platforms for combination immunotherapy. Nature reviews Cancer 2018;18:419-
32. 
[19] Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. 
Oncoimmunology 2016;5:e1115641. 
[20] Desjardins A, Gromeier M, Herndon JE, 2nd, Beaubier N, Bolognesi DP, Friedman AH, et al. 
Recurrent Glioblastoma Treated with Recombinant Poliovirus. The New England journal of 
medicine 2018;379:150-61. 
[21] Chiocca EA, Blair D, Mufson RA. Oncolytic viruses targeting tumor stem cells. Cancer 
research 2014;74:3396-8. 
[22] Mukherjee A, Waters AK, Babic I, Nurmemmedov E, Glassy MC, Kesari S, et al. Antibody 
drug conjugates: Progress, pitfalls, and promises. Human antibodies 2018. 
[23] Norsworthy KJ, Ko CW, Lee JE, Liu J, John CS, Przepiorka D, et al. FDA Approval Summary: 
Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid 
Leukemia. The oncologist 2018;23:1103-8. 
[24] Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in 
relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature biotechnology 
2012;30:631-7. 
[25] Lambert JM, Chari RV. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate 
(ADC) for HER2-positive breast cancer. J Med Chem 2014;57:6949-64. 
[26] Lamb YN. Inotuzumab Ozogamicin: First Global Approval. Drugs 2017;77:1603-10. 
[27] Garcia-Alonso S, Ocana A, Pandiella A. Resistance to Antibody-Drug Conjugates. Cancer 
research 2018;78:2159-65. 
[28] Andreev J, Thambi N, Perez Bay AE, Delfino F, Martin J, Kelly MP, et al. Bispecific Antibodies 
and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of 
HER2 ADCs. Molecular cancer therapeutics 2017;16:681-93. 
[29] Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A Biparatopic 
HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models 
Refractory to or Ineligible for HER2-Targeted Therapy. Cancer cell 2016;29:117-29. 
[30] Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-
mediated cancer therapy: What to expect? Biochemical pharmacology 2016;102:1-6. 
[31] Ding X, Liu D, Booth G, Gao W, Lu Y. Virus-Like Particle Engineering: From Rational Design 
to Versatile Applications. Biotechnol J 2018;13:e1700324. 
[32] Pokorski JK, Steinmetz NF. The art of engineering viral nanoparticles. Molecular 
pharmaceutics 2011;8:29-43. 
[33] Ma Y, Nolte RJ, Cornelissen JJ. Virus-based nanocarriers for drug delivery. Advanced drug 
delivery reviews 2012;64:811-25. 
[34] Schwarz B, Uchida M, Douglas T. Biomedical and Catalytic Opportunities of Virus-Like 
Particles in Nanotechnology. Advances in virus research 2017;97:1-60. 
[35] Wang G, Jia T, Xu X, Chang L, Zhang R, Fu Y, et al. Novel miR-122 delivery system based on 
MS2 virus like particle surface displaying cell-penetrating peptide TAT for hepatocellular 
carcinoma. Oncotarget 2016;7:59402-16. 
[36] Galaway FA, Stockley PG. MS2 viruslike particles: a robust, semisynthetic targeted drug 
delivery platform. Molecular pharmaceutics 2013;10:59-68. 
[37] Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, Lino CA, et al. Cell-specific delivery 
of diverse cargos by bacteriophage MS2 virus-like particles. ACS nano 2011;5:5729-45. 
[38] Tapia-Moreno A, Juarez-Moreno K, Gonzalez-Davis O, Cadena-Nava RD, Vazquez-Duhalt R. 
Biocatalytic virus capsid as nanovehicle for enzymatic activation of Tamoxifen in tumor cells. 
Biotechnol J 2017;12. 
[39] Chao CN, Lin MC, Fang CY, Chen PL, Chang D, Shen CH, et al. Gene Therapy for Human Lung 
Adenocarcinoma Using a Suicide Gene Driven by a Lung-Specific Promoter Delivered by JC Virus-
Like Particles. PloS one 2016;11:e0157865. 
[40] Alemzadeh E, Izadpanah K, Ahmadi F. Generation of recombinant protein shells of Johnson 
grass chlorotic stripe mosaic virus in tobacco plants and their use as drug carrier. Journal of 
virological methods 2017;248:148-53. 
[41] Kato T, Yui M, Deo VK, Park EY. Development of Rous sarcoma Virus-like Particles Displaying 
hCC49 scFv for Specific Targeted Drug Delivery to Human Colon Carcinoma Cells. Pharmaceutical 
research 2015;32:3699-707. 
[42] Deo VK, Kato T, Park EY. Virus-Like Particles Displaying Recombinant Short-Chain Fragment 
Region and Interleukin 2 for Targeting Colon Cancer Tumors and Attracting Macrophages. 
Journal of pharmaceutical sciences 2016;105:1614-22. 
[43] Zochowska M, Piguet AC, Jemielity J, Kowalska J, Szolajska E, Dufour JF, et al. Virus-like 
particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against 
hepatocellular carcinoma. Nanomedicine : nanotechnology, biology, and medicine 2015;11:67-
76. 
[44] Shan W, Chen R, Zhang Q, Zhao J, Chen B, Zhou X, et al. Improved Stable Indocyanine Green 
(ICG)-Mediated Cancer Optotheranostics with Naturalized Hepatitis B Core Particles. Advanced 
materials 2018;30:e1707567. 
[45] Schwarz B, Douglas T. Development of virus-like particles for diagnostic and prophylactic 
biomedical applications. Wiley interdisciplinary reviews Nanomedicine and nanobiotechnology 
2015;7:722-35. 
[46] Lu Y, Chan W, Ko BY, VanLang CC, Swartz JR. Assessing sequence plasticity of a virus-like 
nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery. Proceedings 
of the National Academy of Sciences of the United States of America 2015;112:12360-5. 
[47] Kim S, Kim D, Jung HH, Lee IH, Kim JI, Suh JY, et al. Bio-inspired design and potential 
biomedical applications of a novel class of high-affinity peptides. Angewandte Chemie 
2012;51:1890-4. 
[48] Sharma A, Kapoor P, Gautam A, Chaudhary K, Kumar R, Chauhan JS, et al. Computational 
approach for designing tumor homing peptides. Scientific reports 2013;3:1607. 
[49] Gautam A, Kapoor P, Chaudhary K, Kumar R, Open Source Drug Discovery C, Raghava GP. 
Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and 
theranostics. Current medicinal chemistry 2014;21:2367-91. 
[50] Lu L, Qi H, Zhu J, Sun WX, Zhang B, Tang CY, et al. Vascular-homing peptides for cancer 
therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017;92:187-95. 
[51] David A. Peptide ligand-modified nanomedicines for targeting cells at the tumor 
microenvironment. Advanced drug delivery reviews 2017;119:120-42. 
[52] Ozturk-Atar K, Eroglu H, Calis S. Novel advances in targeted drug delivery. Journal of drug 
targeting 2018;26:633-42. 
[53] Dardevet L, Rani D, Aziz TA, Bazin I, Sabatier JM, Fadl M, et al. Chlorotoxin: a helpful natural 
scorpion peptide to diagnose glioma and fight tumor invasion. Toxins 2015;7:1079-101. 
[54] Ruoslahti E. Tumor penetrating peptides for improved drug delivery. Advanced drug 
delivery reviews 2017;110-111:3-12. 
[55] Svensen N, Walton JG, Bradley M. Peptides for cell-selective drug delivery. Trends in 
pharmacological sciences 2012;33:186-92. 
[56] Pesarrodona M, Crosas E, Cubarsi R, Sanchez-Chardi A, Saccardo P, Unzueta U, et al. Intrinsic 
functional and architectonic heterogeneity of tumor-targeted protein nanoparticles. Nanoscale 
2017;9:6427-35. 
[57] Sanchez JM, Sanchez-Garcia L, Pesarrodona M, Serna N, Sanchez-Chardi A, Unzueta U, et al. 
Conformational Conversion during Controlled Oligomerization into Nonamylogenic Protein 
Nanoparticles. Biomacromolecules 2018;19:3788-97. 
[58] Pesarrodona M, Ferrer-Miralles N, Unzueta U, Gener P, Tatkiewicz W, Abasolo I, et al. 
Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles. 
International journal of pharmaceutics 2014;473:286-95. 
[59] de Pinho Favaro MT, Serna N, Sanchez-Garcia L, Cubarsi R, Roldan M, Sanchez-Chardi A, et 
al. Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich 
peptides. Nanomedicine : nanotechnology, biology, and medicine 2018. 
[60] Unzueta U, Cespedes MV, Ferrer-Miralles N, Casanova I, Cedano J, Corchero JL, et al. 
Intracellular CXCR4(+) cell targeting with T22-empowered protein-only nanoparticles. 
International journal of nanomedicine 2012;7:4533-44. 
[61] Unzueta U, Cespedes MV, Vazquez E, Ferrer-Miralles N, Mangues R, Villaverde A. Towards 
protein-based viral mimetics for cancer therapies. Trends in biotechnology 2015;33:253-8. 
[62] Cespedes MV, Unzueta U, Avino A, Gallardo A, Alamo P, Sala R, et al. Selective depletion of 
metastatic stem cells as therapy for human colorectal cancer. EMBO molecular medicine 2018. 
[63] Serna N, Sanchez-Garcia L, Unzueta U, Diaz R, Vazquez E, Mangues R, et al. Protein-Based 
Therapeutic Killing for Cancer Therapies. Trends in biotechnology 2017. 
[64] Diaz R, Pallares V, Cano-Garrido O, Serna N, Sanchez-Garcia L, Falgas A, et al. Selective 
CXCR4(+) Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of 
Recombinant Ricin. Small 2018:e1800665. 
[65] Sanchez-Garcia L, Serna N, Alamo P, Sala R, Cespedes MV, Roldan M, et al. Self-assembling 
toxin-based nanoparticles as self-delivered antitumoral drugs. Journal of controlled release : 
official journal of the Controlled Release Society 2018. 
[66] Serna NC, M; Sánchez-García, L; Unzueta, U; Sala, R; Sánchez-Chardi, A; Cortés, F; Ferrer-
Miralles, N; Mangues, R; Vázquez, E; Villaverde, A. Peptide-Based Nanostructured Materials with 
Intrinsic Proapoptotic Activities in CXCR4+ Solid Tumors. Advanced Functional Materials 
2017;27:1700919. 
 
 
* [20] Desjardins A, Gromeier M, Herndon JE, 2nd, Beaubier N, Bolognesi DP, Friedman AH, et 
al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. The New England journal of 
medicine 2018;379:150-61. 
A phase I clinical trial testing intratumoral administration of recombinant non-pathogenic 
polio-rhinovirus chimera demonstrates a survival increase in patients with recurrent grade IV 
malignant gliomablastoma, in the absence of neorovirulence. 
 
**[26] Lamb YN. Inotuzumab Ozogamicin: First Global Approval. Drugs 2017;77:1603-10. 
Inotuzumab ozogamicin is an ADC targeted to CD22 and conjugated to calicheamicin, a DNA- 
damaging cytotoxic agent. It has been recently approved for the treatment of adults with 
relapsed or refractory CD22+ B-cell precursor acute lymphoblastic leukemia . 
 
**[32] Schwarz B, Uchida M, Douglas T. Biomedical and Catalytic Opportunities of Virus-Like 
Particles in Nanotechnology. Advances in virus research 2017;97:1-60. 
Representative review of recent advances in VLPs technology and engineering for multiple 
applications in nanotechnology including targeted drug delivery. 
 
*[39] Shan W, Chen R, Zhang Q, Zhao J, Chen B, Zhou X, et al. Improved Stable Indocyanine 
Green (ICG)-Mediated Cancer Optotheranostics with Naturalized Hepatitis B Core Particles. 
Advanced materials 2018;30:e1707567. 
Combined imaging and photothermal therapy over cancer cells by targeted delivery of a 
theranostic drug using Hepatitis B core protein VLPs. 
 
* [51] David A. Peptide ligand-modified nanomedicines for targeting cells at the tumor 
microenvironment. Advanced Drug Delivery Reviews 119 (2017) 120–142.  
An illustrative review of peptide ligands aimed at targeting cells in the tumor 
microenvironment, including interesting discussions on their design as well as an overview on 
ligand-targeted nanomedicines that are currently in development for cancer therapy and 
diagnosis. 
 
** [65] Sanchez-Garcia L, Serna N, Alamo P, Sala R, Cespedes MV, Roldan M, et al. Self-
assembling toxin-based nanoparticles as self-delivered antitumoral drugs. Journal of controlled 
release 274 (2018) 81-92. 
The concept of vehicle-free nanoscale drug is fully supported by the design of multifunctional 
cytotoxic proteins that self-assemble as tumor-targeted smart nanoparticles.  
 
 
 
 
 
Figure 1. Main protein-based approaches to nanoscale drug delivery in cancer. Oncolytic viruses 
(with edited genomes) and viral gene therapy vectors (carrying a therapeutic transgene) exploit 
natural viral properties as cell-targeted nanoparticles for intracellular delivery of nucleic acids, 
that either kill the infected cell or restore a cell function. Cell targeting can be additionally 
modulated by protein engineering. VLPs use structural properties of natural viruses for the 
controlled in vitro packaging of antitumoral drugs (red symbols). Again, targeting can be tailored 
by protein engineering. Drug coacervates are simple non-covalent protein-drug complexes, 
untargeted, in which proteins mainly have stabilizing roles, apart from increasing the size in 
which the drug is presented. ADCs are simple drug nanoconjugates targeted to a specific cell 
receptor. Cell targeting can be also achieved with non-antibody proteins, in the form of either 
nanocojugates or as peptide-functionalized cages or nanovehicles, including liposomes and 
polymeric particles. Self-assembling engineered proteins form virus-inspired nanoparticles that 
can be conjugated with conventional drugs or contain therapeutic protein domains, usually with 
cytotoxic proteins (self-structured protein drugs). This last case is the only so far explored 
example of chemically homogenous nanomedicines in cancer therapies. 
